News

The collection at the Truhlsen-Marmor Museum of the Eye includes more than 38,000 objects, including rare books, instruments and immersive educational materials.

Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.

Huang and 2 OCT co-inventors were honored this week at the White House with the National Medal of Technology and Innovation.

The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.

Technology allows partitioning of sequencing reads into 2 parental genome data sets.

According to the company, the software is designed to streamline the flow of information, surgical planning, and enable electronic medical record and diagnostic device integration.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

According to the company, the clinical trial will assess the safety, efficacy and tolerability of AURN001, a combination cell therapy product.

Physician discusses 5 keys to achieve optimal results for patients

A new, larger 0.6-mm temporary plug is designed with a tapered edge.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.

The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.

Collaboration between ophthalmologists, optometrists can boost early detection.

According to a lawsuit filed in U.S. District Court in Detroit, a policy requires Henry Ford Health and Henry Ford Medical Group (HFMG) employees to undergo a screening assessment for cognition when they reach the age of 70, again at age 75 and each year after that.

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

Developing technology may offer marked improvements in surgical precision

Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.

The FDA has granted temporary discretion to import erythromycin ophthalmic ointment for the treatment of newborns.

Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

Ocular graft-vs-host disease is not the garden variety dry eye.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

According to a human study of older adults, grape intake improved macular pigment accumulation and downregulated harmful biomarkers.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.

According to the United States Attorney’s Office Southern District of Texas, Michael Hochman, MD, is set to be arraigned Oct. 12 before U.S. Magistrate Judge Christopher dos Santos.

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.